Ixekizumab Enhances Quality of Life in Axial Spondyloarthritis
In a groundbreaking study published in Advances in Therapy, researchers have unveiled the efficacy of Ixekizumab, a monoclonal antibody targeting interleukin-17A, in enhancing the lives...